TL;DR: The Drug Enforcement Administration’s Administrative Law Judge proceedings on cannabis rescheduling have advanced meaningfully through mid-2026, with evidentiary hearings underway and industry participants presenting testimony on reclassifying cannabis from Schedule I to Schedule III. A final rule — which would eliminate the IRS Section 280E tax burden for cannabis companies — remains on track for a potential determination before year-end 2026. The outcome will be the most consequential regulatory event in U.S. cannabis history.
Market Analysis
Cannabis stocks have been pricing in a spectrum of outcomes for the DEA rescheduling process throughout 2026, with the MSOS ETF — the most liquid instrument for institutional sector exposure, tracking companies accessible through the cannabis stock tracker — gaining over 25 percent year-to-date through July 24. That performance reflects both improving company fundamentals driven by state-level legalization momentum and sustained optionality pricing on federal action.
The financial stakes of Schedule III reclassification are not hypothetical. IRS Section 280E currently treats state-licensed cannabis retailers as trafficking in a Schedule I or II controlled substance, denying them the ability to deduct ordinary business expenses — including rent, wages, and cost of goods sold above direct production costs. For the largest multi-state operators, the effective tax rate under 280E can exceed 70 to 80 percent of gross income, representing a structural disadvantage with no parallel in any other legal U.S. industry.
Analyst modeling from earlier in 2026 estimated 280E relief would add approximately $0.30 to $0.70 per share in normalized earnings for large-cap MSOs such as Curaleaf Holdings (OTC: CURLF) and Green Thumb Industries (OTC: GTBIF) — both reporting Q2 2026 results within the next two weeks. Earnings calls for those companies will almost certainly include updated management commentary on the rescheduling timeline and capital allocation plans in a post-280E environment.
Regulatory and Market Context
The procedural history of the DEA rescheduling proposal is extensive. The U.S. Department of Health and Human Services issued a formal recommendation to reschedule cannabis in August 2023, citing its accepted medical use and lower abuse potential relative to Schedule I criteria. The DEA published a Notice of Proposed Rulemaking in May 2024, triggering a public comment period and subsequent requests for formal Administrative Law Judge proceedings from several dozen parties — including law enforcement organizations opposing rescheduling and industry participants and medical associations supporting it.
The ALJ hearing process, which commenced in late 2025, involves live testimony, cross-examination, and evidentiary submissions before a presiding Administrative Law Judge. By July 2026, the proceedings are in an active evidence presentation phase, with expert witnesses addressing the pharmacological basis for Schedule III classification, comparative addiction and abuse potential data, and the public health implications of reclassification. The ALJ’s recommended decision — submitted to the DEA Administrator for final determination — is expected in the second half of 2026.
Critically, rescheduling under the Controlled Substances Act does not legalize cannabis at the federal level and does not permit interstate commerce. It does not in itself open federally insured banking for cannabis businesses — that remains a SAFE Banking Act question currently progressing through Congress. What rescheduling accomplishes beyond 280E relief is a normalization signal that reduces perceived regulatory risk for institutional investors currently restricted from cannabis equity exposure by internal compliance frameworks.
State-level legislative momentum continues in parallel. Pennsylvania’s adult-use framework has been advancing through the legislature in 2026, with a floor vote possible before year-end. Florida’s recreational market, approved by voters in 2024, continues to absorb capacity from operators who built medical infrastructure in anticipation of conversion, with licensed retail transactions exceeding early projections in several high-density markets.
Conclusion
The DEA rescheduling process is now at a stage where timing uncertainty, rather than directional uncertainty, is the primary investor variable. The preponderance of evidence in the ALJ proceedings supports the basis for Schedule III reclassification — as HHS itself concluded in 2023. The outstanding question is when the final rule will publish and whether any appellate or Congressional challenge will delay implementation. For cannabis equity investors, the current period represents a window in which 280E relief is not yet priced as a certainty but is increasingly priced as a near-term probability. The Q2 2026 earnings season — beginning with Tilray Brands on July 28 and running through mid-August — will offer management teams their first opportunity since the ALJ hearings commenced to characterize the timeline with specificity, and investor attention will be acute.